TEVA-SPIRONOLACTONE 25 MG
SPIRONOLACTONE : 25 MG · DIN 00613215 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is TEVA-SPIRONOLACTONE?
TEVA-SPIRONOLACTONE 25 MG contains SPIRONOLACTONE : 25 MG. It is listed in the Health Canada Drug Product Database under DIN 00613215, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 29-Jun-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 00613215 |
|---|---|
| Brand name | TEVA-SPIRONOLACTONE |
| Generic / active ingredient | SPIRONOLACTONE : 25 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 25 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C03DA01 SPIRONOLACTONE |
| AHFS class | 24:32.20 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 29-Jun-2011 |
| Original market date | 1984-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code C03DA01 SPIRONOLACTONE. 6 of 10 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| JAMP SPIRONOLACTONE | 100 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02518848 |
| JAMP SPIRONOLACTONE | 25 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02518821 |
| MINT-SPIRONOLACTONE | 100 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | DIN 02488159 |
| MINT-SPIRONOLACTONE | 25 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | DIN 02488140 |
| TEVA-SPIRONOLACTONE | 100 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 00613223 |
| ALDACTONE 100 MG | 100 MG | TABLET | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 00285455 |
| ALDACTONE 25 MG | 25 MG | TABLET | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 00028606 |
| NTP-SPIRONOLACTONE | 100 MG | TABLET | NT PHARMA CANADA LTD | CANCELLED PRE MARKET | DIN 02347628 |
| NTP-SPIRONOLACTONE | 25 MG | TABLET | NT PHARMA CANADA LTD | CANCELLED PRE MARKET | DIN 02347601 |
Who else supplies SPIRONOLACTONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SPIRONOLACTONE appears in 137 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.